Recent Highlights • Pre-launch U.S. product sales of A$1.1 million in second quarter • Successful preparation for U.S. national market launch in January 2019 • 26 abstracts highlighting RECELL® System clinical and economic benefits accepted for presentation at multiple burn conferences, including the American Burn Association (ABA) 51st Annual Meeting • A$41.7 million equity financing […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-31 02:02:322019-02-13 12:10:35AVITA Medical Second Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update
SeaDragon Limited (NZX:SEA) today announces the appointment of Bryan Mogridge to the Board of Directors, with effect from the 1st of February 2019. Bryan has a BSc in Bio-chemistry and was instrumental in building a solid export base for New Zealand wine. In 1998 he was made an Officer of the New Zealand Order of […]
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Second positive […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-28 03:24:032019-02-14 03:26:16Second positive phase 1 trial data for XF-73
RECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019 Valencia, Calif., USA, and Melbourne, Australia, 29 January 2019 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company,today announced that 26 abstracts highlighting theclinical and cost savings benefits of the RECELL® Autologous Cell Harvesting Device […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-28 03:11:482019-02-08 03:14:07AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-25 03:14:052019-02-14 03:20:26Destiny Pharma awarded significant new grant funding up to £1.6 million under new UK-China AMR programme
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma notes release of UK Government’s Vision and 5-year action plan to help tackle anti-microbial resistance (AMR), which includes additional investment in innovation Government’s plan consistent with Destiny Pharma’s objective of developing novel anti-infectives from its proprietary XF platform. Brighton, United Kingdom – 24 January 2019 – Destiny Pharma (AIM: […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-24 03:22:002019-02-14 03:23:31Destiny Pharma notes UK 5-year action plan on AMR
For the purposes of Listing Rule 7.12.1 of the NZX Main Board Listing Rules, SeaDragon Limited (NZX:SEA) (the Company) advises that the following securities have been issued: (a) Class of security: Loan notes ISIN: Not applicable (b) Number issued: 1,000,000 (one million) (c) […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-21 02:31:262019-02-15 02:40:45Notification of issue of securities
Shareholders approve 2nd Tranche of December 2018 equity placement Valencia, Calif., USA, and Melbourne, Australia, 14 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, announce the results of the votes and the proxies received in […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-14 02:21:012019-01-17 02:33:14AVITA Medical Announces Results of Extraordinary General Meeting
Strong market response to the RECELL System approval in advance of U.S. launch with 36 burn centers actively reviewing the product or placing commercial orders Valencia, Calif., USA, and Melbourne, Australia, 8 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has commenced the U.S. national […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-08 02:05:312019-01-17 02:20:18AVITA Medical Announces U.S. National Market Launch of RECELL® System
January 5, 2019 Excerpted from BioWorld MedTech, Volume 22, No.109, June 6, 2018 By David Godkin, Staff Writer The global orthopedic implants market valued at $47 billion in 2016 is expected to grow to $75 billion by 2023. To get a piece of that action, lead investors at Vancouver, B.C.-based Quark Venture Inc. are investing $10 million in Chirp data analytics […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-05 02:50:292019-01-08 02:52:01BioWorld Medtech – Canadian med tech, venture capital firm go global with medical implant analytics
AVITA Medical Second Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update
/in Avita MedicalRecent Highlights • Pre-launch U.S. product sales of A$1.1 million in second quarter • Successful preparation for U.S. national market launch in January 2019 • 26 abstracts highlighting RECELL® System clinical and economic benefits accepted for presentation at multiple burn conferences, including the American Burn Association (ABA) 51st Annual Meeting • A$41.7 million equity financing […]
SeaDragon Limited announces Director changes
/in SeaDragonSeaDragon Limited (NZX:SEA) today announces the appointment of Bryan Mogridge to the Board of Directors, with effect from the 1st of February 2019. Bryan has a BSc in Bio-chemistry and was instrumental in building a solid export base for New Zealand wine. In 1998 he was made an Officer of the New Zealand Order of […]
Second positive phase 1 trial data for XF-73
/in Destiny PharmaTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Second positive […]
AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting
/in Avita MedicalRECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019 Valencia, Calif., USA, and Melbourne, Australia, 29 January 2019 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company,today announced that 26 abstracts highlighting theclinical and cost savings benefits of the RECELL® Autologous Cell Harvesting Device […]
Destiny Pharma awarded significant new grant funding up to £1.6 million under new UK-China AMR programme
/in Destiny PharmaTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma […]
Destiny Pharma notes UK 5-year action plan on AMR
/in Destiny PharmaDestiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma notes release of UK Government’s Vision and 5-year action plan to help tackle anti-microbial resistance (AMR), which includes additional investment in innovation Government’s plan consistent with Destiny Pharma’s objective of developing novel anti-infectives from its proprietary XF platform. Brighton, United Kingdom – 24 January 2019 – Destiny Pharma (AIM: […]
Notification of issue of securities
/in SeaDragonFor the purposes of Listing Rule 7.12.1 of the NZX Main Board Listing Rules, SeaDragon Limited (NZX:SEA) (the Company) advises that the following securities have been issued: (a) Class of security: Loan notes ISIN: Not applicable (b) Number issued: 1,000,000 (one million) (c) […]
AVITA Medical Announces Results of Extraordinary General Meeting
/in Avita MedicalShareholders approve 2nd Tranche of December 2018 equity placement Valencia, Calif., USA, and Melbourne, Australia, 14 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, announce the results of the votes and the proxies received in […]
AVITA Medical Announces U.S. National Market Launch of RECELL® System
/in Avita MedicalStrong market response to the RECELL System approval in advance of U.S. launch with 36 burn centers actively reviewing the product or placing commercial orders Valencia, Calif., USA, and Melbourne, Australia, 8 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has commenced the U.S. national […]
BioWorld Medtech – Canadian med tech, venture capital firm go global with medical implant analytics
/in Canary MedicalJanuary 5, 2019 Excerpted from BioWorld MedTech, Volume 22, No.109, June 6, 2018 By David Godkin, Staff Writer The global orthopedic implants market valued at $47 billion in 2016 is expected to grow to $75 billion by 2023. To get a piece of that action, lead investors at Vancouver, B.C.-based Quark Venture Inc. are investing $10 million in Chirp data analytics […]